- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02789488
Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Polycystic ovary syndrome is considered as clinical and public health consequence involving increase in number of cysts in women at reproductive age. These cysts are under-developed sacs in which eggs are developed. In PCOS, these sacs are unable to release an egg which means ovulation doesn't take place.
The estimated 5-10% prevalence of PCOS is reported in women of reproductive age. A study from Spain also reported that 28.3% prevalence rate of PCOS is among 113 overweight or obese women who were referred to an endocrinology clinic for weight loss. This data was compared with a previously reported prevalence of 6.5% which suggests that the prevalence of PCOS might be markedly increasing with obesity.
PCOS impacts significantly on various hormonal cycles. With PCOS, luteinizing hormone (LH) levels become higher than follicle stimulating hormone (FSH) levels. Because of this increase in LH levels, the LH surge does not take place and ovulation doesn't carry out which results in irregular menstrual cycle. The irregular menstrual period produces oligomenorrhea (few menstrual periods) or amenorrhea (no menstrual periods) and infertility due to irregular or lack of ovulation. PCOS also produces high levels of masculinizing hormones with symptoms of acne and hirsutism, hypermenorrhea involving heavy and prolonged menstrual periods and androgenic alopecia (increase hair thinning and diffused hair loss). The other metabolic syndromes associated with PCOS are increased risk of type 2 diabetes, high cholesterol levels and obesity.
These complications arise because of the genetically determined cause of the PCOS i.e. hyper- secretion of androgens from the ovary which favours excess luteinizing hormone (LH) secretion and insulin resistance. However, insulin resistance with or without a genetic mutation may be the initiator, followed by hyper-androgenism. Thus, insulin resistance is an important contributing factor to abnormal steroidogenesis in PCOS because hyper-insulinemia stimulates the pathway of insulin like growth factor-I (IGF-I) in theca cells of the ovary by cross-reacting with the receptors of IGF. Stimulation of the ovarian theca cells increases the production of androgens (eg, testosterone, androstenedione) which in turn, blocks the down-regulation of androgens by LH surge and leads to the hyper-androgenic environment in the ovary. Because of a decreased level of FSH relative to LH, the ovarian granulosa cells cannot aromatize the androgens to estrogens, which lead to decreased estrogen levels and results in anovulation.
Treatments for PCOS are chosen based on woman's symptoms, age and future pregnancy plans which may include birth control pills to regulate menstruation, insulin-sensitizing medications, ovulation induction to treat infertility, androgen-blocking medications, topical anti-hair-growth medications, etc.
Standardized fenugreek (Trigonella foenum graecum) seed extract (Furocyst) plays an important role in the management of PCOS. It improves glucose-tolerance and insulin-sensitivity, thereby promoting weight loss and moderation of androgen levels in the blood. Standardized fenugreek seeds extract contains a group of furostanolic saponins, derived from fenugreek seeds by an innovative process. It contains rich variety of saponins and flavonoids which have been known to lower the blood lipid levels and play valuable role in improving insulin sensitivity. Standardized fenugreek seeds extract is a dual insulin-sensitizer. In the presence of high fiber furostanolic saponins, cells become more sensitive to insulin & an increase in number of insulin receptor sites occurs. These receptor sites are responsive to insulin to stimulate the cells ability to burn glucose. This decrease in insulin resistance helps in the management of PCOS.
Considering the beneficial effects of standardized fenugreek seed extract, present study was conducted to evaluate the efficacy of fenugreek seeds extract in patients with poly cystic ovary syndrome by assessing reduction in ovarian volume and decrease in the number of ovarian cysts.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Premenopausal women between 18-45 years of age and BMI less than 42
- Diagnosed with PCOS
- Adequate hepatic, renal and hematological functions
- Patients willing to give informed consent in writing
Exclusion Criteria:
- Males
- Post menopausal women
- Women with hysterectomy
- Patients with congenital adrenal hyperplasia
- Patients suffering from Cushing's syndrome
- Patients diagnosed with androgen secreting tumors
- Patients with thyroid dysfunction (T3, T4 level is higher than that in normal women of reproductive age)
- Patients with Hypo-gonadotropic and Hypo-gonadism (central origin of ovarian dysfunction)
- Pregnancy or desire for pregnancy or lactating mothers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Furocyst
Furocyst one caps BID
|
Furocyst one caps BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Ovary volume as assessed by ultrasound
Time Frame: 12 weeks
|
volume in cubic cms
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr Amrita Sarkari Jaipuriar, MS, Garg Hospital,Goalghar .Gorakhpur,UP,India
Publications and helpful links
General Publications
- Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223-36. doi: 10.1056/NEJMra041536. No abstract available.
- Schroder AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM. [Insulin resistance in polycystic ovary syndrome]. Wien Klin Wochenschr. 2003 Dec 15;115(23):812-21. doi: 10.1007/BF03041041. German.
- Hassanzadeh Bashtian M, Emami SA, Mousavifar N, Esmaily HA, Mahmoudi M, Mohammad Poor AH. Evaluation of Fenugreek (Trigonella foenum-graceum L.), Effects Seeds Extract on Insulin Resistance in Women with Polycystic Ovarian Syndrome. Iran J Pharm Res. 2013 Spring;12(2):475-81.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR001/PCOS-5-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poly Cystic Ovary Syndrome
-
Allied Hospital FaisalabadCompleted
-
Benha UniversityCompletedInfertility Poly Cystic Ovary
-
October 6 UniversityRecruitingPoly Cystic Ovary SyndromeEgypt
-
Sohag UniversityRecruitingPoly Cystic Ovary Treatment for InfertilityEgypt
-
Ain Shams UniversityNot yet recruiting
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
Clinical Trials on Fenugreek seeds extract 500 mg
-
Chemical ResourcesCompleted
-
Chemical ResourcesCompleted
-
Jacksonville UniversitySPECNOVA LLCCompletedAging | Testosterone DeficiencyUnited States
-
University of Mary Hardin-BaylorIndus Biotech Ltd. Pvt.CompletedInflammation | Muscle DamageUnited States
-
University of Management and Technology LahoreCompletedGlucose Metabolism Disorders (Including Diabetes Mellitus)Pakistan
-
All India Institute of Medical Sciences, BhubaneswarChemical ResourcesCompletedType-2 Diabetes MellitusIndia
-
Jacksonville UniversitySpecnova, incUnknownMuscle SorenessUnited States
-
Korea Ginseng CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.RecruitingCardiovascular Diseases | Platelet Aggregation | Vasodilation | Blood Pressure DisordersUnited States
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedCoronary Artery Disease | Blood Pressure | Heart Rate | Autonomic Nervous System DiseaseBrazil